Latest Posts:

Sorry, no posts matched your criteria.

Follow Us:

Back To Top

2018

november

Systematised ‘quant’ venture in the sciences

Imagine an approach to venture in which there are models that can predict how likely a given strategy, or venture, is to achieve the desired outcome. This isn’t magic, it is how a lot of PE and hedge funds work. In venture it’s the holy grail, yet it sits in complete contrast the real world…

Full read here (8 min)

may

A new story for Science entrepreneurship

We believe the “Old Story” about science venturing is no longer the whole story. Moreover, it looks to us like it is the dominance of the Old Story itself which is the primary bottleneck to unleashing the impact potential of scientific innovation, rather than infrastructure we have in place in the UK and Europe. If we’re right, the good news is that…

Full read here (4 min)

april

The DSV convergence thesis

Scientific discovery forms the core of our modern lives, yet we still live in a world where a 12% success rate on billion dollar pharmaceutical trials is considered acceptable, the time from lab to application is over 17 yearsand most results can’t be reproduced. At its core, nature can be explained with maths…

Full read here (8 min)

Pharma is entering classic Innovator’s dilemma

Earlier this week a well meaning Goldman Sachs analyst caused uproar by pointing out that it’s going to be really tough to build a good business modelaround gene therapy… so maybe Pharma shouldn’t be wasting their time curing people. Everyone was thinking it so someone had to say it…

Full read here (3 min)

january

Year One

It’s been a busy one. 2000+ applications, 300+ interviews, 53 Founders, 3% acceptance rate, 400+ ideas explored, 19 ventures built, all in really tough areas from digitally accelerated therapeutics to brain machine interfaces, 67% chance of a founder starting a venture, 20 top tier industry partnerships, 13 patents filed and 50+ leading academics working with us to build ventures from across universities from Imperial to Stanford. Here’s how we got there…

Full read here (9 min)

2017

december

Commentary on UK Gov’s Life Science Strategy

The last time I walked the the echoey corridors of the Palace of Westminster (UK parliament), I was a wee 12 year old, on a mission to push forward legislation to prevent the newly privatised water companies pouring raw sewage into cornish water. Not an unreasonable demand I thought at the time, but still one that went ignored until the EU came to the rescue a few years later…

Full read here (5 min)

october

Do deep-tech investments actually make money?

The rhetoric amongst founders, investors and accelerators has changed recently. Consumer facing start-ups and dubious implementations of ‘AI’ (i.e. mostly simple off-the -shelf algorithms) has gone off the boil and investors and founders are increasingly looking towards deep-tech…

Full read here (11 min)

june

Valkyrie: ultra realistic haptics to unlock VR

One of the most difficult things to achieve is perfect alignment of interests and ambitions across a group of people. We’re talking about the start-up equivalent of “Love at First Sight” — you get into a room together and everything clicks. This is especially true for the exceptionally ambitious: those with giant, idiosyncratic visions. Yet this is what we managed to achieve with the founders of Valkyrie…

Full read here (3 min)

uFraction8: Enabling the bio-economy

The bio-economy holds enormous potential, everything from fuel to therapeutics can be produced in modified bacteria without any of the horrific environmental damage and chemicals usually used in these processes. However, there’s one major problem…

Full read here (2 min)

Antiverse: drug development in 18 hours

We first met Rowina whilst running a workshop at Imperial’s incubator on exploring the potential of personalised medicine. With a background in cell free synthesis systems for high yield protein expression she seemed perfect for DSV. We decided to invite her to join as a part time Exec Fellow to develop a game-changing startup; it turned out the ideal opportunity was awaiting!

Full read here (3 min)

may

How Value Materializes at DSV

5 weeks into DSV we were having the same conversation that we’d been having every week for the last 4 weeks. I slap the table, because in situations like these, I am a complete diva: “I just don’t want this to become a table top company”. And I don’t mean a company which could fit on top of a table, adorable as that would be. I mean a company which produces the tops of tables…

Full read here (6 min)

Ways to feed the future

The question we’ve been stewing on at DeepScienceVentures this month: what are the opportunities, challenges and problems intrinsic to the future of food? Here, we focus predominantly on agriculture and plants, leaving the future of meat to a later post…

Full read here (9 min)

2018

november

Systematised ‘quant’ venture in the sciences

Imagine an approach to venture in which there are models that can predict how likely a given strategy, or venture, is to achieve the desired outcome. This isn’t magic, it is how a lot of PE and hedge funds work. In venture it’s the holy grail, yet it sits in complete contrast the real world…

Full read here (8 min)

may

A new story for Science entrepreneurship

We believe the “Old Story” about science venturing is no longer the whole story. Moreover, it looks to us like it is the dominance of the Old Story itself which is the primary bottleneck to unleashing the impact potential of scientific innovation, rather than infrastructure we have in place in the UK and Europe. If we’re right, the good news is that…

Full read here (4 min)

april

The DSV convergence thesis

Scientific discovery forms the core of our modern lives, yet we still live in a world where a 12% success rate on billion dollar pharmaceutical trials is considered acceptable, the time from lab to application is over 17 yearsand most results can’t be reproduced. At its core, nature can be explained with maths…

Full read here (8 min)

Pharma is entering classic Innovator’s dilemma

Earlier this week a well meaning Goldman Sachs analyst caused uproar by pointing out that it’s going to be really tough to build a good business modelaround gene therapy… so maybe Pharma shouldn’t be wasting their time curing people. Everyone was thinking it so someone had to say it…

Full read here (3 min)

january

Year One

It’s been a busy one. 2000+ applications, 300+ interviews, 53 Founders, 3% acceptance rate, 400+ ideas explored, 19 ventures built, all in really tough areas from digitally accelerated therapeutics to brain machine interfaces, 67% chance of a founder starting a venture, 20 top tier industry partnerships, 13 patents filed and 50+ leading academics working with us to build ventures from across universities from Imperial to Stanford. Here’s how we got there…

Full read here (9 min)

2017

december

Commentary on UK Gov’s Life Science Strategy

The last time I walked the the echoey corridors of the Palace of Westminster (UK parliament), I was a wee 12 year old, on a mission to push forward legislation to prevent the newly privatised water companies pouring raw sewage into cornish water. Not an unreasonable demand I thought at the time, but still one that went ignored until the EU came to the rescue a few years later…

Full read here (5 min)

october

Do deep-tech investments actually make money?

The rhetoric amongst founders, investors and accelerators has changed recently. Consumer facing start-ups and dubious implementations of ‘AI’ (i.e. mostly simple off-the -shelf algorithms) has gone off the boil and investors and founders are increasingly looking towards deep-tech…

Full read here (11 min)

june

Valkyrie: Creating the ultra realistic haptics needed to unlock VR

One of the most difficult things to achieve is perfect alignment of interests and ambitions across a group of people. We’re talking about the start-up equivalent of “Love at First Sight” — you get into a room together and everything clicks. This is especially true for the exceptionally ambitious: those with giant, idiosyncratic visions. Yet this is what we managed to achieve with the founders of Valkyrie…

Full read here (3 min)

uFraction8: Enabling the bio-economy

The bio-economy holds enormous potential, everything from fuel to therapeutics can be produced in modified bacteria without any of the horrific environmental damage and chemicals usually used in these processes. However, there’s one major problem…

Full read here (2 min)

Antiverse: Taking drug development from 18 months to 18 hours

We first met Rowina whilst running a workshop at Imperial’s incubator on exploring the potential of personalised medicine. With a background in cell free synthesis systems for high yield protein expression she seemed perfect for DSV. We decided to invite her to join as a part time Exec Fellow to develop a game-changing startup; it turned out the ideal opportunity was awaiting!

Full read here (3 min)

may

How Value Materializes at DSV

5 weeks into DSV we were having the same conversation that we’d been having every week for the last 4 weeks. I slap the table, because in situations like these, I am a complete diva: “I just don’t want this to become a table top company”. And I don’t mean a company which could fit on top of a table, adorable as that would be. I mean a company which produces the tops of tables…

Full read here (6 min)

Ways to feed the future

The question we’ve been stewing on at DeepScienceVentures this month: what are the opportunities, challenges and problems intrinsic to the future of food? Here, we focus predominantly on agriculture and plants, leaving the future of meat to a later post…

Full read here (9 min)